艾迪注射液联合mFOLFOX6方案对晚期结直肠癌化疗患者T淋巴细胞水平及化疗安全性的影响  

Effect of Aidi Injection Combined with mFOLFOX6 Regimen on T Lymphocyte Level and Safety of Chemotherapy in Patients with Advanced Colorectal Cancer

作　　者：张贤 童金凤 江政松 汤蕾 夏云[1] 王志[1] ZHANG Xian;TONG Jinfeng;JIANG Zhengsong;TANG Lei;XIA Yun;WANG Zhi(Department of Oncology,Jiujiang NO.1 People's Hospital,Jiujiang 332000,China;不详)

机构地区：[1]九江市第一人民医院肿瘤科,江西九江332000

出　　处：《中国医学创新》2024年第13期33-38,共6页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(202211877)。

摘　　要：目的:研究艾迪注射液+mFOLFOX6方案运用于晚期结直肠癌化疗中的价值。方法:选择2022年7月—2023年3月九江市第一人民医院纳入的90例晚期结直肠癌化疗患者,按随机数字表法分为两组,各45例。研究组接受艾迪注射液+mFOLFOX6方案,对照组采取mFOLFOX6方案。比较两组毒副反应、症候积分、T淋巴细胞、糖类抗原242(CA242)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、辅助型T细胞(Th)1、Th2、Th1/Th2、生活质量(QOL)。结果:研究组恶心呕吐、便秘、腹泻、骨髓抑制、外周神经毒性的发生率均低于对照组,差异均有统计学意义(P<0.05)。两组用药前的症候积分比较,差异均无统计学意义(P>0.05),研究组用药后的各项积分均较对照组更低,差异均有统计学意义(P<0.05)。两组用药前的T淋巴细胞水平比较,差异均无统计学意义(P>0.05),研究组用药后的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较对照组高,但CD8^(+)低于对照组,差异均有统计学意义(P<0.05)。两组用药前的肿瘤标志物比较,差异均无统计学意义(P>0.05),研究组用药后的CA242、CA19-9、CEA均较对照组更低,差异均有统计学意义(P<0.05)。两组用药前的QOL各项评分比较,差异均无统计学意义(P>0.05),研究组用药后的QOL各项评分均较对照组高,差异均有统计学意义(P<0.05)。两组用药前的免疫指标比较,差异均无统计学意义(P>0.05),研究组用药后的Th1、Th1/Th2均较对照组更低,但Th2高于对照组,差异均有统计学意义(P<0.05)。结论:艾迪注射液+mFOLFOX6方案应用于晚期结直肠癌患者的效果更为理想,可促进患者T淋巴细胞及肿瘤标志物水平改善,减轻患者症状,并调节免疫,提高生活质量,毒副反应较少,安全性更高。Objective:To study the value of Aidi Injection+mFOLFOX6 regimen in chemotherapy of advanced colorectal cancer.Method:A total of 90 patients with advanced colorectal cancer enrolled in Jiujiang NO.1 People's Hospital from July 2022 to March 2023 were selected and divided into two groups according to random number table method,with 45 cases respectively.The study group received Aidi Injection+mFOLFOX6 regimen,and the control group received mFOLFOX6 regimen.The toxic and side effects,syndrome scores,T lymphocytes,carbohydrate antigen 242(CA242),carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA),helperT cells(Th)1,Th2,Th1/Th2 and quality of life(QOL)were compared between the two groups.Result:The incidences of nausea,vomiting,constipation,diarrhea,myelosuppression and peripheral neurotoxicity in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in syndrome scores between the two groups before medication(P>0.05),and scores in the study group after medication were lower than those in the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in T lymphocyte levels between the two groups before treatment(P>0.05),after treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the study group were higher than those in the control group,but level of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in levels of tumor markers between the two groups before treatment(P>0.05),and the levels of CA242,CA19-9 and CEA in the study group after treatment were lower than those in the control group,the differences were statistically significant(P<0.05).There were no statistically significant differences in QOL scores between the two groups before medication(P>0.05),and QOL scores in the study group after medication were higher than those

关 键 词：mFOLFOX6方案 艾迪注射液 晚期结直肠癌 化疗 T淋巴细胞 

分 类 号：R735.34[医药卫生—肿瘤]